Literature DB >> 7693972

HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2.

S P Lee1, W A Thomas, R J Murray, F Khanim, S Kaur, L S Young, M Rowe, M Kurilla, A B Rickinson.   

Abstract

Cytotoxic T-lymphocyte (CTL) responses induced by persistent Epstein-Barr virus (EBV) infection in normal B-lymphoid tissues could potentially be directed against EBV-positive malignancies if expression of the relevant viral target proteins is maintained in tumor cells. For malignancies such as nasopharyngeal carcinoma and Hodgkin's disease, this will require CTL targeting against the nuclear antigen EBNA1 or the latent membrane proteins LMP1 and LMP2. Here we analyze in detail a B95.8 EBV-reactivated CTL response which is specific for LMP2 and restricted through a common HLA allele, A2.1. We found that in vitro-reactivated CTL preparations from several A2.1-positive virus-immune donors contained detectable reactivity against A2.1-bearing target cells expressing either LMP2A or the smaller LMP2B protein from recombinant vaccinia virus vectors. Peptide sensitization experiments then mapped the A2.1-restricted response to a single epitope, the nonamer CLGGLLTMV (LMP2A residues 426 to 434), whose sequence accords well with the proposed peptide binding motif for A2.1. Most Caucasian and African virus isolates (whether of type 1 or type 2) were identical in sequence to B95.8 across this LMP2 epitope region, although 2 of 12 such isolates encoded a Leu-->Ile change at epitope position 6. In contrast, most Southeast Asian and New Guinean isolates (whether of type 1 or type 2) constituted a different virus group with a Cys-->Ser mutation at epitope position 1. CTLs raised against the B95.8-encoded epitope were nevertheless able to recognize these variant epitope sequences in the context of A2.1 whether they were provided exogenously as synthetic peptides or generated endogenously in B cells transformed with the variant viruses. A CTL response of this kind could have therapeutic potential in that it is directed against a protein expressed in many EBV-positive malignancies, is reactive across a range of virus isolates, and is restricted through a relatively common HLA allele.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7693972      PMCID: PMC238208     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

1.  Standards for total serum protein assays--a collaborative study.

Authors:  B T Doumas
Journal:  Clin Chem       Date:  1975-07       Impact factor: 8.327

Review 2.  Immune surveillance against Epstein-Barr virus.

Authors:  D J Moss; S R Burrows; R Khanna; I S Misko; T B Sculley
Journal:  Semin Immunol       Date:  1992-04       Impact factor: 11.130

3.  Recognition of the Epstein-Barr virus-encoded nuclear antigens EBNA-4 and EBNA-6 by HLA-A11-restricted cytotoxic T lymphocytes: implications for down-regulation of HLA-A11 in Burkitt lymphoma.

Authors:  R Gavioli; P O De Campos-Lima; M G Kurilla; E Kieff; G Klein; M G Masucci
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

4.  Consistent transcription of the Epstein-Barr virus LMP2 gene in nasopharyngeal carcinoma.

Authors:  P Busson; R McCoy; R Sadler; K Gilligan; T Tursz; N Raab-Traub
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

5.  Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy.

Authors:  T E Starzl; M A Nalesnik; K A Porter; M Ho; S Iwatsuki; B P Griffith; J T Rosenthal; T R Hakala; B W Shaw; R L Hardesty
Journal:  Lancet       Date:  1984-03-17       Impact factor: 79.321

6.  Release of infectious Epstein-Barr virus by transformed marmoset leukocytes.

Authors:  G Miller; M Lipman
Journal:  Proc Natl Acad Sci U S A       Date:  1973-01       Impact factor: 11.205

7.  Cytotoxic T cell recognition of Epstein-Barr virus-infected B cells. III. Establishment of HLA-restricted cytotoxic T cell lines using interleukin 2.

Authors:  L E Wallace; M Rowe; J S Gaston; A B Rickinson; M A Epstein
Journal:  Eur J Immunol       Date:  1982-12       Impact factor: 5.532

8.  Probable identification of an HL-A second-locus antigen associated with a high risk of nasopharyngeal carcinoma.

Authors:  M J Simons; G B Wee; S H Chan; K Shanmugaratnam
Journal:  Lancet       Date:  1975-01-18       Impact factor: 79.321

9.  Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development.

Authors:  R Khanna; S R Burrows; M G Kurilla; C A Jacob; I S Misko; T B Sculley; E Kieff; D J Moss
Journal:  J Exp Med       Date:  1992-07-01       Impact factor: 14.307

10.  Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies.

Authors:  R J Murray; M G Kurilla; J M Brooks; W A Thomas; M Rowe; E Kieff; A B Rickinson
Journal:  J Exp Med       Date:  1992-07-01       Impact factor: 14.307

View more
  54 in total

1.  Identification of naturally processed and HLA-presented Epstein-Barr virus peptides recognized by CD4(+) or CD8(+) T lymphocytes from human blood.

Authors:  W Herr; E Ranieri; A Gambotto; L S Kierstead; A A Amoscato; L Gesualdo; W J Storkus
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

2.  Sequence variations of Epstein-Barr virus LMP2A gene in gastric carcinoma in Japan.

Authors:  M Tanaka; Y Kawaguchi; J Yokofujita; M Takagi; Y Eishi; K Hirai
Journal:  Virus Genes       Date:  1999       Impact factor: 2.332

3.  Latent antigen vaccination in a model gammaherpesvirus infection.

Authors:  E J Usherwood; K A Ward; M A Blackman; J P Stewart; D L Woodland
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

Review 4.  Adoptive immunotherapy for Hodgkin's lymphoma.

Authors:  Alana A Kennedy-Nasser; Catherine M Bollard; Cliona M Rooney
Journal:  Int J Hematol       Date:  2006-06       Impact factor: 2.490

5.  Immediate-early transactivator Rta of Epstein-Barr virus (EBV) shows multiple epitopes recognized by EBV-specific cytotoxic T lymphocytes.

Authors:  S Pepperl; G Benninger-Döring; S Modrow; H Wolf; W Jilg
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

Review 6.  Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.

Authors:  R J O'Reilly; T N Small; E Papadopoulos; K Lucas; J Lacerda; L Koulova
Journal:  Springer Semin Immunopathol       Date:  1998

7.  Epstein-Barr virus gene expression in post-transplant lymphoproliferative disorders.

Authors:  M Rowe; G Niedobitek; L S Young
Journal:  Springer Semin Immunopathol       Date:  1998

Review 8.  Immunotherapy II: Antigens, receptors and costimulation.

Authors:  P F Searle; L S Young
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

9.  Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies.

Authors:  R Khanna; S R Burrows; D J Moss; S L Silins
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

10.  A recombinant adenovirus expressing an Epstein-Barr virus (EBV) target antigen can selectively reactivate rare components of EBV cytotoxic T-lymphocyte memory in vitro.

Authors:  S M Morgan; G W Wilkinson; E Floettmann; N Blake; A B Rickinson
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.